Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.

Stewart GD, O'Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock AL, Nanda J, O'Donnell M, Mackay A, Mullen P, McNeill SA, Riddick AC, Aitchison M, Berney D, Bex A, Overton IM, Harrison DJ, Powles T.

Eur Urol. 2014 Nov;66(5):956-63. doi: 10.1016/j.eururo.2014.04.007. Epub 2014 May 10.

2.

Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.

Dornbusch J, Zacharis A, Meinhardt M, Erdmann K, Wolff I, Froehner M, Wirth MP, Zastrow S, Fuessel S.

PLoS One. 2013 Sep 27;8(9):e76386. doi: 10.1371/journal.pone.0076386. eCollection 2013.

3.

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.

Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S.

BJU Int. 2010 Sep;106(6):772-8. doi: 10.1111/j.1464-410X.2010.09218.x. Epub 2010 Mar 2.

4.

Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.

Gigante M, Li G, Ferlay C, Perol D, Blanc E, Paul S, Zhao A, Tostain J, Escudier B, Negrier S, Genin C.

Anticancer Res. 2012 Dec;32(12):5447-51.

PMID:
23225450
6.

Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma.

Trávníček I, Branžovský J, Kalusová K, Hes O, Holubec L, Pele KB, Ürge T, Hora M.

Anticancer Res. 2015 Oct;35(10):5661-6.

PMID:
26408740
7.

A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.

Stubbs C, Bardoli AD, Afshar M, Pirrie S, Miscoria M, Wheeley I, Porfiri E.

Anticancer Res. 2017 Jan;37(1):253-259.

PMID:
28011500
8.

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.

Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA.

Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50. doi: 10.1007/s00280-014-2539-0. Epub 2014 Aug 7.

9.

Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer.

Stewart GD, O'Mahony FC, Laird A, Eory L, Lubbock AL, Mackay A, Nanda J, O'Donnell M, Mullen P, McNeill SA, Riddick AC, Berney D, Bex A, Aitchison M, Overton IM, Harrison DJ, Powles T.

Clin Cancer Res. 2015 Sep 15;21(18):4212-23. doi: 10.1158/1078-0432.CCR-15-0207. Epub 2015 May 26.

10.

CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.

de Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, Li Z, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

J Urol. 2009 Aug;182(2):728-34. doi: 10.1016/j.juro.2009.03.077. Epub 2009 Jun 18.

PMID:
19539328
11.

Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment.

Tostain J, Li G, Gentil-Perret A, Gigante M.

Eur J Cancer. 2010 Dec;46(18):3141-8. doi: 10.1016/j.ejca.2010.07.020. Epub 2010 Aug 13. Review.

PMID:
20709527
12.

The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Shin SJ, Jeon YK, Cho YM, Lee JL, Chung DH, Park JY, Go H.

Oncologist. 2015 Nov;20(11):1253-60. doi: 10.1634/theoncologist.2015-0151. Epub 2015 Sep 30.

13.
14.

Sunitinib, sorafenib and mTOR inhibitors in renal cancer.

Radulovic S, Bjelogrlic SK.

J BUON. 2007 Sep;12 Suppl 1:S151-62. Review.

PMID:
17935273
15.

Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.

Kawai Y, Osawa T, Kobayashi K, Inoue R, Yamamoto Y, Matsumoto H, Nagao K, Hara T, Sakano S, Nagamori S, Matsuyama H.

Asian Pac J Cancer Prev. 2015;16(14):5687-90.

16.

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.

Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B.

Cancer Treat Rev. 2016 Nov;50:109-117. doi: 10.1016/j.ctrv.2016.09.002. Epub 2016 Sep 10. Review.

PMID:
27664394
17.

Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.

Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naïmi B, Porcher R, de La Taille A, Menashi S, Calvo F, Mourah S.

PLoS One. 2010 May 19;5(5):e10715. doi: 10.1371/journal.pone.0010715.

18.

Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.

Phuoc NB, Ehara H, Gotoh T, Nakano M, Kamei S, Deguchi T, Hirose Y.

Oncol Rep. 2008 Sep;20(3):525-30.

PMID:
18695901
19.

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.

Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS.

Clin Cancer Res. 2003 Feb;9(2):802-11.

20.

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.

Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C.

Lancet Oncol. 2011 Nov;12(12):1143-50. doi: 10.1016/S1470-2045(11)70266-2. Epub 2011 Oct 17.

PMID:
22015057

Supplemental Content

Support Center